Cover Image
市場調查報告書

全球生技仿製藥單株抗體市場預測

Biosimilar Monoclonal Antibodies World Market Forecast 2016-2021

出版商 Labrinth Analytics LTD 商品編碼 359773
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
全球生技仿製藥單株抗體市場預測 Biosimilar Monoclonal Antibodies World Market Forecast 2016-2021
出版日期: 2016年03月21日 內容資訊: 英文
簡介

全球生技仿製藥單株抗體市場,從2015年的3億6,500萬美元,預計到2021年達到46億6,370萬美元。市場預計2016年∼2021年以53.6%的年複合成長率成長。

本報告提供全球生技仿製藥單株抗體市場相關調查分析,趨勢與收益 (成果、預測) 、推動因素、阻礙因素,機會與課題等系統性資訊。

第1章 過去的資料

第2章 全球生技仿製藥單株抗體市場主要企業

  • Pfizer, Inc.
  • Novartis AG
  • Reliance Life Sciences
  • Allergan plc
  • Coherus BioSciences, Inc.
  • Biocon
  • Dr. Reddy's Laboratories Ltd.
  • Boehringer Ingelheim GmbH
  • BioXpress Therapeutics SA
  • Intas Pharmaceuticals Limited
  • BIOCAD
  • Genor BioPharma Co. Ltd
  • Celltrion, Inc.

第3章 生技仿製藥單株抗體:各主要藥物/化合物

  • 全球市場
  • 收益預測
  • Rituximab
  • Infliximab
  • Abciximab
  • Adalimumab
  • Bevacizumab

第4章 主要國家的生技仿製藥單株抗體市場

  • 亞洲市場
  • 中國
  • 韓國
  • 日本
  • 其他亞洲市場
  • 歐洲市場
  • 俄羅斯
  • 德國
  • 英國
  • 法國
  • 義大利
  • 其他的歐洲市場
  • 北美市場
  • 美國
  • 加拿大
  • 南美市場
  • 巴西
  • 墨西哥
  • 其他南美市場
  • 其他地區市場

第5章 現在可以利用的開發平台藥物市場定性分析

  • Remsima/Inflectra
  • Infimab
  • Mabtas
  • AcellBia
  • MABALL
  • AbcixiRel
  • Herzuma
  • CANMAb
  • BI695500
  • CT-P10
  • BI695501
  • BCD-022
  • FKB327
  • FKB238
  • PF-05280586
  • MK 8808
  • ABP 215

第6章 生技仿製藥單株抗體市場定性分析

  • 單株抗體
  • 生技仿製藥概要
  • 各種法規
  • 市場動態
  • 價值鏈分析
  • 平均價格分析
  • SWOT分析
  • 大環境分析
  • 藥物比較及其他治療
  • 現在可以利用的藥物的市場方案
  • 未來市場預測

第7章 表格的清單

第8章 圖的清單

第9章 企業、其他刊載企業

目錄

The global biosimilar monoclonal antibodies market was valued at US$ 365.0 Mn in 2015 and is expected to reach US$ 4,663.7 Mn, at a CAGR of 53.6% during 2016-2021. India was the largest market for biosimilar monoclonal antibodies, accounted for 16.8% of the global market. The dominance of India is majorly due to number of are in the pipeline, major market players are based in India, and preference for low cost biosimilar by Indian Population. Rituximab was the largest segment in terms of revenue in the global biosimilar monoclonal antibodies market and accounted for 46.7% share in 2015. Major biologics are losing their patent, innovative product in the pipeline and growing healthcare infrastructure in the developing nations would boost market growth in the future. Biosimilar monoclonal antibodies represent richest products in the pipeline development and it expected that it will increase the competitive rivalry among players during the forecast period after commercialization of the pipeline products.

image1

image2

image3

image4

Even without the new regulations from the SFDA, the Chinese biosimilar mAb submarket will continue to grow rapidly, driven by the launch of many new biosimilar mAbs. Drug developers are used to working within the current regulations in China, so will be able to continue with successful development programmes in the near future. In its 12th Five Year Plan, the Chinese government highlighted biopharmaceuticals as a key market for growth towards 2016. Investment from the government will help drive growth in the biosimilars market in the first half of the forecast period.

Further government investment in healthcare coverage will also act as a growth driver for biosimilars in the coming 5 years. The Chinese government is aiming to provide some level of healthcare coverage to the entire Chinese population by 2020. In order to make this affordable, healthcare will have to rely on the cheapest versions of drugs available, including biosimilar mAbs. In 2013, more than 95% of Chinese residents have some form of healthcare coverage, up from 15% in 2003. As well as investing heavily in this expanded healthcare programme - $180bn was spent between 2009 and 2011 - the government is able to afford this policy by implementing mandatory price cuts on important drugs. In the future, these price cuts could hit biosimilar mAbs particularly those targeting key disease areas, such as cancer.

Due to the fact that Chinese biosimilar companies already compete in the mAb market sector, the launch of new products will not provide the same driver for market growth as in the US and EU. However, the rising prevalence of chronic disease in China, as well as improved diagnosis, will expand the potential market for biosimilar mAbs. Improved regulatory processes will also improve the quality of biosimilar mAbs in China during those 10 years

Why purchase this report?

This study investigates commercial trends and revenues of Biosimilar Monoclonal Antibodies Market Forecast 2016- 2021, as well as including recent historical data. That investigation also discusses forces driving and restraining revenue expansion at the overall world market, submarket and national level. The study also examines opportunities and challenges for that industry and market, as well as economic forces affecting companies.

In particular, this new analysis will

  • Help your research, analyses, decisions, presentations, proposals and business plans
  • Highlight commercial opportunities - submarkets, products and countries with the highest sales potentials, also giving you multilevel revenue forecasts to 2026
  • Benefit your knowledge of the industry, helping your authority and influence
  • Provide intelligence on competitors and their activities
  • Keep you up to date with commercial developments - events shaping that business
  • Help you evaluate companies in clinical provider services
  • Explain trends to watch - strengths, weaknesses, opportunities and threats
  • Help your organisation succeed through your getting insight on that industry and market, especially technological and commercial prospects from 2016.

How we compile our reports

  • Due to our extensive database we are able to merge primary and secondary research to produce accurate market analysis.
  • Our reports contain quantitative and qualitative analytical content, covering the present and future of important healthcare markets. While our reports are market-centred, we include medical and technical information. We include analyses of unmet market needs from the present looking forward. Our sales forecasting assesses the magnitude and effects of driving and restraining forces, to determine annual

Table of Contents

  • Report Summary
  • Introduction to Biosimilar Monoclonal Antibodies Market 2015
  • What information can you expect to gain from this report?
  • Market Segmentation
  • Leading National Market for Biosimilar Monoclonal Antibodies

1. Historical Data

  • 1.1 Biosimilar Monoclonal Antibodies Market 2012
  • 1.2 Biosimilar Monoclonal Antibodies Market 2013
  • 1.3 Biosimilar Monoclonal Antibodies Market 2014
  • 1.4 Biosimilar Monoclonal Antibodies Market 2015

2. Leading Companies in the World Biosimilar Monoclonal Antibodies Market

  • 2.1 Pfizer, Inc.
  • 2.2 Novartis AG
  • 2.3 Reliance Life Sciences
  • 2.4 Allergan plc
  • 2.5 Coherus BioSciences, Inc.
  • 2.6 Biocon
  • 2.7 Dr. Reddy's Laboratories Ltd.
  • 2.8 Boehringer Ingelheim GmbH
  • 2.9 BioXpress Therapeutics SA
  • 2.10 Intas Pharmaceuticals Limited
  • 2.11 BIOCAD
  • 2.12 Genor BioPharma Co. Ltd
  • 2.13 Celltrion, Inc.

3. Biosimilar Monoclonal Antibodies by Major Drug Class/Compound, 2015 - 2021

  • 3.1 The Global Market for Biosimilar Monoclonal Antibodies in 2015
  • 3.2 The World Biosimilar Monoclonal Antibodies Market: Revenue Forecasts 2015-2026
  • 3.3 Rituximab Market Forecast 2016 - 2021
  • 3.4 Infliximab Market Forecast 2016 - 2021
  • 3.5 Abciximab Market Forecast 2016 - 2021 3.6 Trastuzumab Market Forecast 2016 - 2021
  • 3.7 Adalimumab Market Forecast 2016 - 2021
  • 3.8 Bevacizumab Market Forecast 2016 - 2021

4. Leading National Markets for the Biosimilar Monoclonal Antibodies, 2016-2021

  • 4.1 Asia Biosimilar Monoclonal Antibodies Market: Regional Forecast 2016-2021
  • 4.2 The India Market Forecast 2016-2021
  • 4.3 The China Market Forecast 2016-2021
  • 4.4 The South Korea Market Forecast 2016-2021
  • 4.5 The Japan Market Forecast 2016-2021
  • 4.6 The Rest of Asia Market Forecast 2016-2021
  • 4.7 The Europe Market Forecast 2016-2021
  • 4.8 The Russia Market Forecast 2016-2021
  • 4.9 The Germany Market Forecast 2016-2021
  • 4.10 The United Kingdom Market Forecast 2016-2021
  • 4.11 The France Market Forecast 2016-2021
  • 4.12 The Italy Market Forecast 2016-2021
  • 4.13 The rest of Europe Market Forecast 2016-2021
  • 4.14 The North America Market Forecast 2016-2021
  • 4.15 The U.S. Market Forecast 2016-2021
  • 4.16 The Canada Market Forecast 2016-2021
  • 4.17 The Latin America Market Forecast 2016-2021
  • 4.18 The Brazil Market Forecast 2016-2021
  • 4.19 The Mexico Market Forecast 2016-2021
  • 4.20 The Rest of Latin America Market Forecast 2016-2021
  • 4.21 The Rest of the World Market Forecast 2016-2021

5. Qualitative Analysis for Presently Available and Pipeline Drugs Market, 2016-2026

  • 5.1 Remsima/Inflectra
  • 5.2 Infimab
  • 5.3 Mabtas
  • 5.4 AcellBia
  • 5.5 MABALL
  • 5.6 AbcixiRel
  • 5.7 Herzuma
  • 5.8 CANMAb
  • 5.9 BI695500
  • 5.10 CT-P10
  • 5.11 BI695501
  • 5.12 BCD-022
  • 5.13 FKB327
  • 5.14 FKB238
  • 5.15 PF-05280586
  • 5.16 MK 8808
  • 5.17 ABP 215

6. Qualitative Analysis for Biosimilar Monoclonal Antibodies Market, 2016-2026

  • 6.1 Monoclonal Antibodies
  • 6.2 Biosimilar Overview
  • 6.3 Various Regulations
  • 6.4 Market Dynamics
  • 6.5 Value Chain Analysis
  • 6.6 Average Pricing Analysis
  • 6.7 SWOT Analysis
  • 6.8 Pestle Analysis
  • 6.9 Comparison between drugs and Other Treatment
  • 6.10 Market Scenario for Presently Available Drugs
  • 6.11 Future Market Outlook

7. List of Tables

  • Table 1 Pfizer, Inc.: Historical Sales ($m, AGR%), 2011-2014
  • Table 2 Novartis: Historical Sales ($m, AGR%), 2011-2014
  • Table 3 Allergan: Historical Sales ($m, AGR%), 2011-2014
  • Table 4 Coherus BioSciences, Inc: Historical Sales ($m, AGR%), 2011-2014
  • Table 5 Biocon: Historical Sales ($m, AGR%), 2011-2014
  • Table 6 Dr. Reddy's Laboratories Ltd: Historical Sales ($m, AGR%), 2011-2014
  • Table 7 Boehringer Ingelheim GmbH: Historical Sales ($m, AGR%), 2011-2014
  • Table 8 Intas Pharmaceuticals Limited: Historical Sales ($m, AGR%), 2011-2014
  • Table 9 Celltrion, Inc.: Historical Sales ($m, AGR%), 2011-2014
  • Table 10 Global Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 11 Rituximab Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 12 Infliximab Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 13 Abciximab Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021 Table 14 Trastuzumab Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 15 Adalimumab Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 16 Bevacizumab Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 17 Market Share Analysis by Major Compound/Clas, 2015 (%)
  • Table 18 Asia Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 19 India Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 20 China Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 21 South Korea Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 22 Japan Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 23 Rest of Asia Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 24 Europe Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 25 Russia Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 26 Germany Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 27 United Kingdom Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 28 France Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 29 Italy Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 30 Rest of Europe Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 31 North America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 32 The U.S. Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 33 Canada Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 34 Latin America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 35 Brazil Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 36 Mexico Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 37 Rest of the Latin America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 38 Rest of the World Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 39 Market Share Analysis by Country, 2015 (%)
  • Table 40 SWOT Analysis of the Biosimilar Monoclonal Antibodies Market
  • Table 41 Pestle Analysis of the Biosimilar Monoclonal Antibodies Market

8. Lists of Figures

  • Figure 1 Global Biosimilar Monoclonal Antibodies Market Segmentation Overview, 2015
  • Figure 2 Pfizer, Inc.: Historical Sales ($m, AGR%), 2011-2014
  • Figure 3 Novartis: Historical Sales ($m, AGR%), 2011-2014
  • Figure 4 Allergan plc: Historical Sales ($m, AGR%), 2011-2014
  • Figure 5 Coherus Biosciences, Inc.: Historical Sales ($m, AGR%), 2011-2014
  • Figure 6 Biocon: Historical Sales ($m, AGR%), 2011-2014
  • Figure 7 Dr. Reddy's Laboratories Ltd.: Historical Sales ($m, AGR%), 2011-2014
  • Figure 8 Boehringer Ingelheim GmbH: Historical Sales ($m, AGR%), 2011-2014
  • Figure 9 Intas Pharmaceuticals Limited: Historical Sales ($m, AGR%), 2011-2014
  • Figure 10 Celltrion, Inc.: Historical Sales ($m, AGR%), 2011-2014
  • Figure 11 Global Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 12 Rituxiab Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 13 Infliximab Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 14 Abciximab Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021 Figure 15 Trastuzumab Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 16 Adalimumab Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 17 Bevacizumab Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 18 Market Share Analysis by Compound/Drugs, 2015 (%)
  • Figure 19 Asia Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 20 India Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 21 China Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 22 South Korea Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 23 Japan Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 24 Rest of Asia Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 25 Europe Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 26 Russia Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 27 Germany Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 28 United Kingdom of Europe Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 29 France Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 30 Italy Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 31 Rest of Europe Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 32 North America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 33 The U.S. Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 34 Canada Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 35 Latin America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 36 Brazil Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 37 Mexico of Latin America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 38 Rest of Latin America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 39 Rest of the World Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 40 Market Share Analysis by Country (%)

9 Companies and Other Organizations Mentioned

  • EMA (European Medicines Agency)
  • FDA (US Food and Drug Administration)
  • Merck & Co.
  • MHLW (Ministry of Health, Labour, and Welfare)
  • MHRA (Medicines and Healthcare Products Regulatory Agency)
  • NICE (the National Institute for Health and Care Excellence)
  • Pfizer, Inc.
  • Novartis AG
  • Reliance Life Sciences
  • Allergan plc
  • Coherus BioSciences, Inc.
  • Biocon
  • Dr. Reddy's Laboratories Ltd.
  • Boehringer Ingelheim GmbH
  • BioXpress Therapeutics SA
  • Intas Pharmaceuticals Limited
  • BIOCAD
  • Genor BioPharma Co. Ltd
  • Celltrion, Inc.

The list continues....

Back to Top